Moderna has begun the rolling submission procedure with the US Food and Drug Administration for a Biologics License Application for the licensure of its mRNA vaccine to prevent Covid-19 among individuals aged 18 years and older. The company is expected to continue submitting data in the coming weeks, along with a request for a priority review.
Indian pharmaceutical company Biological E. has signed a licensing agreement with Canada-based biotech Providence Therapeutics to manufacture the company’s mRNA Covid-19 vaccine in India. The company is expected to run a clinical trial of Providence’s vaccine in India, thereby seeking an emergency use approval for the jab. Biological E. has also signed a deal to produce about 600 million doses of the Johnson & Johnson Covid-19 vaccine annually.
The UK is in discussions with Oxford and AstraZeneca regarding the procurement of additional doses of their Covid-19 vaccine, which has been designed to fight the beta coronavirus variant first identified in South Africa. The UK will be funding the trials for the vaccine. The country has already secured 100 million doses of the AstraZeneca jab, but the new doses will be tailored to fight the B.1.351 variant, the health ministry stated.